dc.creator | Manta, S. | en |
dc.creator | Kiritsis, C. | en |
dc.creator | Dimopoulou, A. | en |
dc.creator | Parmenopoulou, V. | en |
dc.creator | Kollatos, N. | en |
dc.creator | Tsotinis, A. | en |
dc.creator | Komiotis, D. | en |
dc.date.accessioned | 2015-11-23T10:38:47Z | |
dc.date.available | 2015-11-23T10:38:47Z | |
dc.date.issued | 2014 | |
dc.identifier.issn | 22113525 | |
dc.identifier.uri | http://hdl.handle.net/11615/30668 | |
dc.description.abstract | In the search of effective, selective and nontoxic antiviral agents, a variety of nucleoside analogues have been synthesized, with different functionalities in the carbohydrate moiety and/or the heterocyclic base. Nucleoside analogues bearing double or triple bonds are recognized as an important class of biologically active compounds and appear to be prominent drugs in the management of several viral infections, including HSV, HIV, HBV, HCV and HCMV. Currently, unsaturated nucleoside mimetics, such as stavudine, abacavir and entecavir have been approved for the treatment of viral infections, while elvucitabine and β-L-2'-F-d4C are in clinical trials. The purpose of this review is to give an update of the recent developments on nucleosides and nucleoside analogues with unsaturation, in both cyclic and acyclic forms, which possess promising therapeutic potential, mainly antiviral. It covers analogues with ring sizes from three to six and provides useful data, aiming at enhancing chemical reactivity as a result of the sugar and base conformations. © 2014 Bentham Science Publishers. | en |
dc.source.uri | http://www.scopus.com/inward/record.url?eid=2-s2.0-84891766028&partnerID=40&md5=b99496fe57dcdd74b628c9d2f5d1acbb | |
dc.subject | Acyclic | en |
dc.subject | Antiviral | en |
dc.subject | Base modified | en |
dc.subject | Carbocyclic | en |
dc.subject | Exomethylene | en |
dc.subject | TSAO | en |
dc.subject | Unsaturated nucleosides | en |
dc.subject | 1',2' seco 4' C branched nucleoside | en |
dc.subject | 4 amino 2 butenyl acyclic nucleoside | en |
dc.subject | 4 amino 2 butenyl acyclic pyrimidine nucleoside | en |
dc.subject | 5 phosphopent 2 en yl nucleosides | en |
dc.subject | 6 azauracil acyclonucleoside | en |
dc.subject | abacavir | en |
dc.subject | acyclic nucleoside | en |
dc.subject | arylethynyltriazole acyclonucleoside | en |
dc.subject | bitriazolyl acyclonucleoside | en |
dc.subject | carbocyclic nucleoside | en |
dc.subject | carbocyclic unsaturated nucleoside | en |
dc.subject | cyclobutyl nucleoside | en |
dc.subject | cyclopentyl nucleoside | en |
dc.subject | cyclopropyl nucleoside | en |
dc.subject | elvucitabine | en |
dc.subject | entecavir | en |
dc.subject | exocyclic methylene nucleoside | en |
dc.subject | nucleoside analog | en |
dc.subject | stavudine | en |
dc.subject | thio unsaturated nucleoside | en |
dc.subject | unclassified drug | en |
dc.subject | antiviral activity | en |
dc.subject | chemical structure | en |
dc.subject | clinical trial (topic) | en |
dc.subject | cytomegalovirus infection | en |
dc.subject | hepatitis B | en |
dc.subject | hepatitis C | en |
dc.subject | herpes simplex | en |
dc.subject | human | en |
dc.subject | Human immunodeficiency virus infection | en |
dc.subject | metabolism | en |
dc.subject | review | en |
dc.subject | structure activity relation | en |
dc.subject | unsaturation | en |
dc.title | Unsaturation: An important structural feature to nucleosides' antiviral activity | en |
dc.type | journalArticle | en |